A neutrophil phagocytosing bacteria.
Blood Research.2017;52(1):9-9. doi:10.5045/br.2017.52.1.9
Blood Research
1969 to Present ISSN: 2287-979X
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
Refractory anemia with ring sideroblasts and thrombocytosis.
Blood Research.2017;52(1):8-8. doi:10.5045/br.2017.52.1.8
Lymphoglandular bodies in bone marrow aspirate smears.
Blood Research.2017;52(1):7-7. doi:10.5045/br.2017.52.1.7
No abstract available.
Bone Marrow*
Bone Marrow*
Blood Research.2017;52(1):3-6. doi:10.5045/br.2017.52.1.3
No abstract available.
Lymphoma*
Lymphoma*
Alternative approaches to preserve MSC progenitor potency.
Blood Research.2017;52(1):1-2. doi:10.5045/br.2017.52.1.1
No abstract available.
Family ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells ; Preservation, Biological
Family ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells ; Preservation, Biological
Management of hemophilia in Korea: the past, present, and future.
Blood Research.2014;49(3):144-145. doi:10.5045/br.2014.49.3.144
Is a cure for CML without allogeneic stem cell transplantation around the corner?.
Blood Research.2014;49(3):141-143. doi:10.5045/br.2014.49.3.141
No abstract available.
Stem Cell Transplantation*
Stem Cell Transplantation*
Way to go to exploit NK cells' versatile talents for cancer immunotherapy.
Blood Research.2014;49(3):139-140. doi:10.5045/br.2014.49.3.139
Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation.
Blood Research.2014;49(1):29-35. doi:10.5045/br.2014.49.1.29
BACKGROUND: Hyperleukocytosis caused by acute lymphoblastic leukemia (ALL) is associated with early morbidity and mortality due to hyperviscosity arising from the excessive number of leukocytes.This study was designed to assess the incidence of hyperleukocytosis, survival outcomes, and adverse features among pediatric ALL patients with hyperleukocytosis. METHODS: Between January 2001 and December 2010, 104 children with previously untreated ALL were enrolled at the Pusan National University Hospital. All of them were initially stratified based on the National Cancer Institute (NCI) risk; 48 (46.2%) were diagnosed with high-risk ALL. The medical charts of these patients were retrospectively reviewed. RESULTS: Twenty (19.2%) of the 104 children with ALL had initial leukocyte counts of >100x10(9)/L, and 11 patients had a leukocyte count of >200x10(9)/L. Male gender, T-cell phenotype, and massive splenomegaly were positively associated with hyperleukocytosis. Common early complications during induction therapy included renal dysfunction, and central nervous system hemorrhage. The complete remission (CR) rate for the pediatric ALL patients with hyperleukocytosis (94.1%) was similar to the overall CR rate (95.6%). The estimated 3-year event free survival (EFS) and overall survival of ALL children with hyperleukocytosis were 75.0% and 81.2%, respectively. However, patients with initial leukocyte counts >200x10(9)/L had a lower EFS than those with initial leukocyte counts 100-200x109/L (63.6% vs. 100%; P=0.046). CONCLUSION: The outcome of pediatric ALL cases with an initial leukocyte count >200x10(9)/L was very poor, probably due to early toxicity-related death during induction therapy.
Busan ; Central Nervous System ; Child ; Disease-Free Survival ; Hemorrhage ; Humans ; Incidence ; Leukocyte Count ; Male ; Mortality ; National Cancer Institute (U.S.) ; Phenotype ; Precursor Cell Lymphoblastic Leukemia-Lymphoma* ; Retrospective Studies ; Splenomegaly ; T-Lymphocytes
Busan ; Central Nervous System ; Child ; Disease-Free Survival ; Hemorrhage ; Humans ; Incidence ; Leukocyte Count ; Male ; Mortality ; National Cancer Institute (U.S.) ; Phenotype ; Precursor Cell Lymphoblastic Leukemia-Lymphoma* ; Retrospective Studies ; Splenomegaly ; T-Lymphocytes
Blood Research.2014;49(1):22-28. doi:10.5045/br.2014.49.1.22
BACKGROUND: The coexistence of t(9;22)(q34;q11.2) and inv(16)(p13q22) chromosomal abnormalities is extremely uncommon, and only a small number of such cases have been reported. Here, we characterized 7 cases of hematologic malignancy exhibiting t(9;22) and inv(16) coexistence. METHODS: We reviewed the cytogenetic data for hematologic malignancies treated at the Catholic Blood and Marrow Transplantation Center between January 2004 and June 2013. We identified 7 cases exhibiting t(9;22) and inv(16) coexistence. In addition, we analyzed mutations in the IKZF1, NPM1, FLT3, N-RAS, K-RAS, c-KIT, and TP53 genes. RESULTS: Four cases of chronic myelogenous leukemia (CML; 1 chronic phase, 2 accelerated phase, and 1 blast phase) and 3 cases of acute myeloid leukemia (AML; 1 de novo and 2 therapy-related) were identified. The percentages of circulating blasts and bone marrow eosinophils were higher in AML cases than in CML cases (53% vs. 5% and 30% vs. 5.5%, respectively). The proportions of each chromosomal abnormality were used along with follow-up karyotyping results to identify secondary changes. In BCR/ABL, a p210 fusion transcript was associated with CML, whereas a p190 fusion transcript was associated with AML. One patient with AML harbored 2 mutations: c-KIT D816V and TP53 E11Q. All patients except 1 with CML blast phase sustained clinical remission after treatment, which included an imatinib mesylate regimen. CONCLUSION: This study shows that observations of bone marrow morphology, initial and follow-up cytogenetic studies, and karyotyping of BCR/ABL1 and CBFB/MYH11 provide valuable information for characterizing hematologic malignancies exhibiting t(9;22) and inv(16) coexistence.
Blast Crisis ; Bone Marrow ; Chromosome Aberrations* ; Cytogenetics ; Eosinophils ; Follow-Up Studies ; Genes, p53 ; Hematologic Neoplasms* ; Humans ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Leukemia, Myeloid, Acute ; Mesylates ; Imatinib Mesylate
Blast Crisis ; Bone Marrow ; Chromosome Aberrations* ; Cytogenetics ; Eosinophils ; Follow-Up Studies ; Genes, p53 ; Hematologic Neoplasms* ; Humans ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Leukemia, Myeloid, Acute ; Mesylates ; Imatinib Mesylate
Country
Republic of Korea
Publisher
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
ElectronicLinks
http://synapse.koreamed.org/LinkX.php?code=3072BREditor-in-chief
Seog-Woon Kwon
journal@bloodresearch.or.kr
Abbreviation
Blood Res
Vernacular Journal Title
ISSN
2287-979X
EISSN
2288-0011
Year Approved
2007
Current Indexing Status
Currently Indexed
Start Year
1969
Description
Blood Research is a peer-reviewed open-access journal and delivers important clinical, translational and basic research results in hematology to the readers worldwide. The research areas covered by Blood Research include hematopoiesis, stem cell biology, stem cell transplantation, thrombosis, hemostasis, hematologic malignancy, pediatric hematology, laboratory hematology, immunohematology, transfusion medicine, immunology, and other hematology-related fields. Blood Research publishes Original Articles, Review Articles, Editorials, Perspectives, Letters to the Editor, and Images of Hematology. It is published online (http://bloodresearch.or.kr) and in print quarterly (March 31, June 30, September 30, and December 31). Any physicians or researchers throughout the world can submit a manuscript written in English.
Previous Title
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)